Table 1 Effect of SG2000 on the growth of canine cancer cells and canine normal cells following a 1Â h or continuous (96Â h) exposure
From: Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours
Cell Line | Cell Type | GI50 (nM)a | |
|---|---|---|---|
1 h | Continuous | ||
C2 | Mast cell | 0.33 ± 0.84b | <0.03b |
ARCE | Mast cell | >100 | 4.10 ± 0.87 |
CMeC-1 | Melanoma, cutaneous (primary) | >100 | 17.33 ± 2.33 |
CMeC-2 | Melanoma, cutaneous (derived from CMeC-1, metastatic in mouse model) | >100 | 11.0 ± 3.78 |
12 | Melanoma, oral | 63.63 ± 45 | 7.83 ± 1.16 |
KMeC | Melanoma, oral | 4.73 ± 2.22 | <0.03 |
LMeC | Melanoma, oral (metastatic mandibular lymph node) | 24.0 ± 3.21 | 1.60 ± 0.79 |
DH82 | Monocyte/macrophage/histiocytic sarcoma | >100 | 4.0 ± 2.0 |
A72 | Connective tissue tumour | 47.0 ± 3.51 | 0.83 ± 0.07 |
DEN | Haemangiosarcoma | 45.0 ± 2.5 | 0.75 ± 0.08 |
D17 | Osteosarcoma | 47.5 ± 2.5 | 0.92 ± 0.57 |
CF33MG | Mammary gland carcinoma | 9.0 ± 3.58 | 0.99 ± 0.01 |
CF35MG | Mammary gland (normal) | >100 | 6.0 ± 0.86 |
MDCK | Kidney epithelial (normal) | >100 | 28.33 ± 8.33 |